发明申请
US20090117132A1 Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
审中-公开
抗Ctla-4抗体和含Cpg基因的合成寡核苷酸联合治疗癌症治疗
- 专利标题： Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
- 专利标题（中）： 抗Ctla-4抗体和含Cpg基因的合成寡核苷酸联合治疗癌症治疗
-
申请号： US11988396申请日： 2006-06-30
-
公开(公告)号： US20090117132A1公开(公告)日： 2009-05-07
- 发明人: David Robert John Readett , Jarl Ulf Birger Jungnelius , Jesus Gomez-Navarro , Douglas Hanson , Arthur M. Krieg
- 申请人： David Robert John Readett , Jarl Ulf Birger Jungnelius , Jesus Gomez-Navarro , Douglas Hanson , Arthur M. Krieg
- 申请人地址： US NY New York US MA Wellesley
- 专利权人： Pfizer, Inc.,Coley Pharmaceutical Group, Inc.
- 当前专利权人： Pfizer, Inc.,Coley Pharmaceutical Group, Inc.
- 当前专利权人地址： US NY New York US MA Wellesley
- 国际申请： PCT/US2006/025711 WO 20060630
- 主分类号： A61K39/395
- IPC分类号： A61K39/395 ; A61P35/00
摘要：
The invention relates to administration of an anti-CTLA-4 antibody, particularly human antibodies to human CTLA-4, such as those having amino acid sequences of antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.2.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and MDX-010, in combination with an immunostimulatory nucleotide, i.e, CpG ODN PF3512676, for treatment of cancer. The invention relates to administering a combination of an anti-CTLA-4 antibody and CpG ODN PF3512676 as neoadjuvant, adjuvant, first-line, second-line, and third-line therapy of cancer, whether localized or metastasized, and at any point(s) along the disease continuum (e.g, at any stage of the cancer).